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ess: asandford@mrl.ubcSummary Background: Although variation in the human leukocyte antigen (HLA)
locus is associated with various diseases, there have been a limited number of
studies that have examined the possible role of HLA in chronic obstructive pulmonary
disease (COPD). Only HLA-B7 has been shown to be correlated with low forced
expiratory volume in 1 s (FEV1) in Caucasians; however, this finding has not been
replicated. The aim of this study was to investigate the contribution of the HLA-B7
allele to COPD and to rate of decline of lung function.
Methods: We determined the prevalence of HLA-B7 in a group of COPD patients
and a non-obstructed control group of smokers by using a polymerase chain reaction-
based genotyping assay. We also determined the prevalence of HLA-B7 in smokers
selected from the National Heart Lung and Blood Institute, Lung Health Study for
having the fastest and slowest decline of lung function.
Results: No significant difference was found in the frequency of HLA-B7 between
the COPD and non-obstructed groups. There was also no significant association of
HLA-B7 with rate of decline of lung function.
Conclusion: These data indicate that HLA-B7 does not contribute to COPD or rate
of decline of FEV1 in smokers.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
806 9008;
.ca (A.J. Sandford).Introduction
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality in devel-
oped countries.1,2 This disease is characterized by
irreversible airflow limitation, increased pulmonaryed.
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lished risk factors for the pathogenesis of COPD are
cigarette smoking and severe a1-antitrypsin defi-
ciency. However, clustering of COPD within families
without deficiency of a1-antitrypsin
3,4 and inter-
individual variation in susceptibility to cigarette
smoking5 suggest that additional risk factors,
possibly genetic factors, contribute to the devel-
opment of COPD.
Despite the contribution of human leukocyte
antigen (HLA) allelic variation to various diseases,
the role of HLA class I alleles in the pathogenesis of
COPD has not been extensively investigated. There
have been a limited number of studies which
describe association between HLA class I genes
and COPD.6,7 In a previous report, only the HLA-B7
allele was shown to be a risk factor for the
development of COPD.6 Although the finding was
noteworthy because HLA-B7 is one of the predomi-
nant HLA types in Caucasians,8 there has been no
replication of this result. In this study, we have
investigated the putative association of HLA-B7
with COPD by using a case–control approach in
smokers. In addition, we investigated the contribu-
tion of HLA-B7 to rate of decline of lung function in
smokers by using the Lung Health Study (LHS). The
LHS was designed to investigate the impact of early
intervention on the course of cigarette smoke-
induced COPD.9 Lung function, as measured by
forced expiratory volume in 1 s (FEV1), normally
increases to a maximal value at adulthood, remains
stable for 10–15 years, and then declines,10 and
COPD may develop because of an accelerated rate
of decline.
Therefore, the aim of this study was to clarify the
role of HLA-B7 in genetic susceptibility to COPD and
rate of decline of FEV1 by employing two different
study designs.Methods
Subjects for the case and control study
Subjects for this study were recruited from patients
admitted to St Paul’s Hospital to undergo lobar or
lung resection surgery for a localized lung cancer.
Prior to surgery, all patients gave informed consent
and completed an interviewer-administered ques-
tionnaire regarded smoking history, occupational
exposure to dust or fumes, and respiratory symp-
toms. FEV1, forced vital capacity (FVC) and FEV1/
FVC ratio were calculated. Patients in whom the
lung lesion was obstructing a segmental or larger
bronchus were excluded from this study as this mayinfluence lung function. All patients selected for
this study were Caucasians. Any patients who had
functional or pathologic evidence of a process
other than those associated with COPD, and non-
smokers were also excluded from this study. Of
these who remained, individuals with FEV1o80%
predicted and FEV1/FVCo70% were classified as
having COPD and placed into the obstructed
category; those with FEV1485% predicted and
FEV1/FVC475% were classified as non-obstructed.
In total, 113 patients were classified as obstructed
and 61 patients were classified as non-obstructed.
DNA for genotyping was extracted from frozen lung
tissue or formalin-fixed lung tissue using a standard
phenol/chloroform protocol or from blood using the
QIAamp DNA BloodMaxi kit (QIAGEN Inc., Mississau-
ga, Ontario). None of the individuals were homo-
zygous for the Z allele of the a1-antitrypsin gene.Individuals from the LHS
Individuals were selected from the participants in
the National Heart, Lung and Blood Institute, Lung
Health Study. The design of this multi-center,
randomized clinical trial has been described in
detail elsewhere.11 Study participants were healthy
current smokers, 35–60 years of age, who had
spirometric signs of early COPD. During 5 years of
follow up, 3216 subjects continued to smoke and
from this cohort we selected the 303 with the
fastest rate of decline of FEV1 (decline in
FEV143.0% of predicted value per year) and the
324 who had no decline of FEV1 (increase in
FEV140.4% of predicted value per year). In total,
613 of these samples were successfully genotyped
for HLA-B7. Of this group, we studied the Caucasian
individuals separately. Other ethnic groups were of
insufficient sample size to provide statistically
meaningful comparison, and were excluded from
statistical analysis. Therefore, 581 Caucasian (277
fastest decline and 304 non-decline) subjects
remained for statistical analysis. None of the
individuals were homozygous for the Z allele of
the a1-antitrypsin gene.Genotyping
The subjects were genotyped by polymerase chain
reaction (PCR) assay by using the published HLA-B7
group-specific primer.12 The sense oligonucleotide
primer and anti-sense primer were designed from
exon 3 of the HLA-B gene which was amplified as a
119bp PCR product. The sequence of sense primer
was 50-CAA GTG GGA GGC GGC CCG TGA-30 and
anti-sense primer was 50-TGG TAC CAG CGC GCT
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contained amplifiable DNA, internal control primers
that amplified a 394bp fragment of the Coxsackie-
adenovirus receptor gene (exon 2)13 were added in
each reaction mixture. The sequence of the control
sense primer was 50-CTG GGC ATC TCT TGA GTT
TGG A-30, and the anti-sense primer was 50-ACT
GGC AAG GTG ATG GAC ACA T-30.
Optimized PCR conditions for HLA-B7 typing were
as follows: the PCR reaction mixture in a final
volume of 20 ml consisted of 100 ng genomic DNA,
1.5mM MgCl2 for frozen tissue and blood-derived
DNA samples and 2.5mM MgCl2 for formalin-fixed
samples, 200 mM each of dATP, dCTP, dGTP and
dTTP, 0.4 mM of each HLA-B7 primer and 0.5 mM of
each control primer, and 0.5 U DNA Taq Polymerase
(Hotstar Taq, Qiagen Inc., Mississauga, Ontario).
PCR amplification was performed in a PCR EXPRESS
Thermal Cycler (Thermo Hybrid, Ashford, Middle-
sex, UK). PCR conditions for cycling were optimized
using the touch down method14 as follows: initial
denaturation step at 95 1C for 15min, followed by 5
cycles of 94 1C for 30 s (denaturation), 68 1C for 30 s
(annealing), and 72 1C for 45 s (extension), followed
by 10 cycles with a decreased annealing tempera-
ture at 67 1C, 20 cycles at 66 1C and a final
extension for 10min at 72 1C. PCR products were
loaded on 2% agarose gels stained with ethidium
bromide and visualized in ultra-violet illumination.Statistical analysis
The results are presented as the prevalence of HLA-
B7 positive individuals (containing both heterozy-
gotes and homozygotes for HLA-B7). The differ-
ences in genotype frequencies between the groups
were assessed by w2 tests. The associations were
also analyzed by logistic regression to adjust for
potential confounding factors such as age, sex and
smoking history (pack years). Since differences in
cigarette consumption over the course of the Lung
Health Study could also influence the rate ofTable 1 Characteristics of the study subjects in the CO
shown as mean7SEM.
COPD (n ¼ 113)
Male/Female 85/28
Age (years) 64.370.8
Smoking history (pack years) 57.272.9
FEV1 (% predicted) 59.371.3
FEV1/FVC1 (%) 57.570.9
Number of packs of cigarettes smoked per day number of ydecline of lung function we also included the
average cigarettes smoked per day over the course
of the study as a confounding variable. All tests
were performed using the JMP Statistics software
package (SAS Institute Inc.). P-values of o0.05
were considered to be statistically significant.
Values for continuous variables are expressed as
mean (7SE).Results
The characteristics of the 174 subjects in the
case–control study and the 581 LHS participants
are shown in Tables 1 and 2, respectively. There
were significant differences in several potentially
confounding factors between each group. There-
fore, the frequencies of genotypes between groups
were analyzed by logistic regression to adjust for
these factors. In the case–control study, the
frequencies of HLA-B7 positivity in the COPD and
non-obstructed groups were 23.9% and 34.4%,
respectively, (Fig. 1a) but the difference between
the groups was not significant. The odds ratio
adjusted for age, sex and smoking history was 0.53
(95% CI 0.25–1.10, P ¼ 0.09). In the LHS cohort, the
frequencies of HLA-B7 positivity in the fastest and
non-decline groups were 23.8% and 26.3%, respec-
tively, (Fig. 1b) and there was also no significant
difference between these two groups. The odds
ratio for HLA-B7 positivity adjusted for age, sex,
smoking history, cigarettes smoked per day over the
course of the study, bronchodilator response,
methacholine response and baseline lung function
was 0.83 (95% CI 0.53–1.29, P ¼ 0.41). The allele
frequencies of HLA-B7 in these study groups, if
Hardy–Weinberg equilibrium is assumed, were 0.12
and 0.13 for the case–control and LHS groups,
respectively. These allele frequencies are similar to
the reported allele frequency (0.134) in Cauca-
sians.8PD and non-obstructed groups. Continuous variables
Non-obstructed (n ¼ 61) P-value
32/29 0.002
62.371.4 0.18
40.674.3 0.001
98.871.3 —
79.670.5 —
ears smoking.
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Table 2 Characteristics of the fast and non-decliner study groups.
Fast decliners (n ¼ 277) Non-decliners (n ¼ 304) P-value
Male/Female 161/116 202/102 0.04
Age (years) 49.570.4 47.670.4 0.0007
Smoking history (pack years) 41.671.0 37.771.0 0.007
Cigarettes smoked per dayy 25.670.6 22.470.6 0.0003
Baseline FEV1(%) predicted
z 72.570.5 75.770.5 o0.0001
Rate of decline in lung functiony 4.1470.06 1.0870.04 o0.0001
Bronchodilator response (%)z 3.570.3 5.870.3 o0.0001
Methacholine response (O’Connor slope) 23.572.0 7.870.9 o0.0001
Values for continuous variables are means7SE
Number of packs of cigarettes smoked per day number of years smoking.
yAverage over the five years of the Lung Health Study.
zLung function at the start of the Lung Health Study.
yChange in lung function per year over a 5 year period measured as % predicted FEV1.
zPercent change in FEV1 from baseline in response to a bronchodilator.
Responsiveness of the airways to methacholine expressed as percent decline in FEV1 per final cumulative dose of
methacholine administered.
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Fig. 1 Prevalence of HLA-B7 positivity in the study
groups. (a) Comparison between the COPD and non-
obstructed groups. The P-value shown is from the logistic
regression model adjusting for age, sex and smoking
history. (b) Comparison between the fastest decliner and
non-decliner groups. The P-value shown is from the
logistic regression model adjusting for age, sex, smoking
history, methacholine response, bronchodilator response
and baseline lung function.
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The association between HLA types and numerous
diseases have been extensively studied becauseHLA mediated responses are integral to the human
immune system and are involved in chronic
inflammatory reactions. However, the role of
polymorphisms of HLA genes in COPD has been
poorly studied. The association between COPD and
an HLA gene was described in 1983 by Kauffmann
and colleagues.6 They found a significantly higher
HLA-B7 frequency in a group of non-smokers who
had low FEV1 compared with a group of heavy
smokers who had normal FEV1 (odds ratio
(OR) ¼ 3.8) in a French population. This finding
suggests that HLA-B7 is a susceptibility allele for
COPD independent of exposure to cigarette smoke.
In 1990, Maranetra and colleagues showed a
significant increase in HLA-Bw60 frequency in a
group with low ventilatory drive compared with
normal ventilatory drive (OR ¼ 42) among COPD
patients in the Thai population.7 This result
suggests that HLA-Bw60 might be related to
ventilatory response to CO2 in COPD, although not
correlated with the risk of COPD itself. This finding,
however, may not be relevant to other populations
since HLA-Bw60 is commonly found in South East
Asians (allele frequency 8–16%) but is rarer in other
populations e.g. in Caucasians the frequency is
3–5%.15 Recently, HLA typing was also performed in
a Japanese patient group who had diffuse pan-
bronchiolitis (DPB) which is a distinctive form of
obstructive lung disease of unknown etiology.16,17
The results demonstrated an increased prevalence
of HLA-Bw54 in the DPB patients compared with the
control group (relative risk ¼ 13.3 and OR ¼ 3.4).
HLA-Bw54 is specifically found in East Asian
populations and is seldom found in other ethnic
groups. The fact that DPB is also limited to East
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between HLA-Bw54 and DPB.
On the basis of findings mentioned above, we
focused on the HLA-B7 allele as a potential risk
factor for COPD in Caucasian populations. However,
our data did not show a significant association
between HLA-B7 and COPD. Although there was no
significant difference between the case and control
groups, the genotype frequency of HLA-B7 was
slightly higher in the non-obstructed group (34.4%)
than in the COPD group (23.9%), which was a trend
opposite to the results of Kauffmann et al.6 In this
study, we also investigated whether HLA-B7 was
associated with an accelerated rate of decline of
lung function. This phenotype is likely to result in
the development of COPD if the rate of decline
remains constant. This is the first study to
investigate the influence of an HLA gene on this
phenotype; however, we also found no contribution
of HLA-B7 to rate of decline of lung function even
with the use of a large sample size. With any
negative study it is important to calculate the
power of the experimental design to detect a
difference. Given the numbers in this study we
should have been able to detect a relative risk of
X3.1 for HLA-B7 as a risk factor for COPD andX2.0
for HLA-B7 as a risk factor for rapid decline.
Therefore, although we cannot rule out the
possibility that the lack of association seen in this
study was due to type 2 error we did have sufficient
power to detect an effect of the magnitude
(OR ¼ 3.8) reported by Kauffmann et al.6 However,
another possible cause of a false negative result
could be the differences in recruitment and
phenotype definition between the present study
and that of Kauffmann et al.6
In this study there were significant differences
between the COPD patients and controls and
between the fast and slow decliners in regard to
important confounding factors such as exposure to
cigarette smoke. It is likely that these differences
contributed to the development of COPD and a
rapid rate of decline of lung function. Therefore,
we have attempted to correct for these differences
in the logistic regression analyses. However, while
cigarette smoking is clearly the most important
environmental risk factor for COPD we believe that
it does not completely explain the pathogenesis of
this disease. For example, epidemiological studies
have shown that only 10–20% of smokers develop
symptomatic COPD18 and differences in cigarette
smoke exposure account for only 15% of the
variation in lung function.19 In the subset of the LHS
investigated in this study, rate of decline of lung
function was poorly correlated with pack-years
(correlation coefficient, R2 ¼ 0.02) and cigaretteconsumption over the course of the study
(R2 ¼ 0.02). Therefore, we believe that it is
important to look for additional factors involved
in the pathogenesis of COPD and the decline in lung
function.
In conclusion, we consider that the lack of
association in this study indicates that HLA-B7 does
not contribute substantially to the risk of COPD and
an accelerated rate of decline of lung function.Acknowledgments
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